PCAS

Capital/Financing Update • Feb 15, 2016

PCAS 8% BONDS DATED- 31/12/2016 BUY BACK

Longjumeau, 15th February 2016,

PCAS announces they have repurchased a total of 7 439 PCAS' 8% Bonds dated 31/12/2016 (FR 0010480707) out of the 33 333 bonds issued in 2007, representing approximately 22,3% of the outstanding bonds.

This operation, which will achieve savings in financial charges, fits in the PCAS' financial debt optimization strategy.

ABOUT PCAS

PCAS specialises in the development and production of complex molecules for Life Sciences and Innovative Technologies. With 7% of its turnover dedicated to R&D and a wide international presence, PCAS is the preferred industrial partner of market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments, and also includes two subsidiaries with very strong potential: Protéus in biotechnology and Enersens in high-performance insulation. With a particularly high standard of performance, PCAS achieved net sales of €179.1 million in 2015 and employs nearly 900 people in six countries.

For more information about PCAS: www.pcas.com

Vincent Touraille / Eric Moissenot PCAS

PCAS NewCap

Emmanuel Huynh / Louis-Victor Delouvrier NewCap Financial Communication & investors relations

Tel. : +33 1 44 71 98 53 pcas@newcap.eu

Tel. : +33 1 69 79 61 32 www.pcas.com